Sandoz Inc.West Princeton, New Jersey, United States
2111: Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
Tuesday, October 28, 202510:30 AM - 12:30 PM Central Time
Disclosure information not submitted.
